DGAP-News: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 11, 2015 at 3:15 AM

DGAP-News: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN GLYCOVAXYN TO GSK

DGAP-News: Edmond de Rothschild Investment Partners / Key word(s): Mergers & Acquisitions EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN GLYCOVAXYN TO GSK 11.02.2015 / 09:00 --------------------------------------------------------------------- PRESS RELEASE February 11th, 2015 EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN GLYCOVAXYN, TO GSK. This operation is the seventh trade sale of BioDiscovery 3, the fifteenth from the BioDiscovery funds Edmond de Rothschild Investment Partners announced today that its BioDiscovery 3 portfolio company, GlycoVaxyn AG, a privately held specialist vaccine biopharmaceutical company, has been acquired by GlaxoSmithKline (GSK) in an all-cash transaction valuing the company at approximately $212 million. GlycoVaxyn, founded in 2004, is a spin out of the Swiss Polytechnic Institute of ZÃ¼rich. It has developed a biological conjugation platform which enables the development of a new generation of conjugate vaccines against major bacterial infections. Vaccines this type are protecting children and adults against several infections among others pneumonia, meningitides, and the role of vaccination to prevent bacterial infections is becoming increasingly important with the development of resistance to antibiotic treatments. The company which signed a major collaboration with GSK in 2012, is in Phase I with a vaccine candidate against E. coli infections and is expected to initiate a Phase I for a vaccine against Shigellosis (severe diarrhea) in the US soon. Edmond de Rothschild Investment Partners led the series B round of Glycovaxyn in 2009. Glycovaxyn was the second investment of BioDiscovery 3, a specialized life science investment fund managed by Edmond de Rothschild Investment Partners. Raised in 2008, the Fund has invested from 2008 to 2012 in a portfolio of 14 companies. So far seven of these companies have been sold through private transactions, four have been listed on public financial markets, and the remaining three are still privately held active companies. About Edmond de Rothschild Investment Partners Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group, which is specialized in asset management and private banking (EUR 133.6bn under management, nearly 2,800 employees spread across 31 offices, branches and subsidiaries throughout the world). Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de Rothschild. Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It currently has more than EUR1.3 billion under management which is being invested primarily as life sciences venture capital and growth capital. Within Edmond de Rothschild Investment Partners, its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The Team has raised EUR450 million through its Biodiscovery franchise and is currently investing BioDiscovery 4. Since inception in 2001, BioDiscovery Funds have invested in 49 companies, of which 15 have been sold and 14 listed on public financial markets. 17 are still active in the portfolios. BioDiscovery Funds, including BioDiscovery 4, are venture capital funds dedicated to professional investors. These funds are not authorized by the AutoritÃ© des MarchÃ©s Financiers and may adopt special investment rules. For more information: www.edrip.fr Contacts Edmond de Rothschild Investment Partners Gilles NobÃ©court g.nobecourt@edr.com Tel: +33 1 40 17 25 41 EDMOND DE ROTHSCHILD (France) Laetitia Guillot-Tantay T. + 331 40 17 89 26 l.guillot-tantay@edr.com MC SERVICES AG Raimund Gabriel T. + 49 89 21 02 28 30 raimund.gabriel@mc-services.eu --------------------------------------------------------------------- 11.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 321793 11.02.2015

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...